These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 7525924)

  • 1. Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity.
    Donevan SD; Yamaguchi S; Rogawski MA
    J Pharmacol Exp Ther; 1994 Oct; 271(1):25-9. PubMed ID: 7525924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against non-NMDA receptor-mediated excitotoxicity by GYKI 52466 in mature telencephalic cultures of the rat.
    Kovács AD; Egyed A
    Neurobiology (Bp); 1996; 4(1-2):59-72. PubMed ID: 9116695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The new 2,3-benzodiazepine derivative EGIS-8332 inhibits AMPA/kainate ion channels and cell death.
    Vegh MG; Kovács AD; Kovács G; Szabó G; Tihanyi K; Hársing LG; Lévay G
    Neurochem Int; 2007 Feb; 50(3):555-63. PubMed ID: 17147974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential antagonism of alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid-preferring and kainate-preferring receptors by 2,3-benzodiazepines.
    Wilding TJ; Huettner JE
    Mol Pharmacol; 1995 Mar; 47(3):582-7. PubMed ID: 7700255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3,5-Dihydro-4H-2,3-benzodiazepine-4-thiones: a new class of AMPA receptor antagonists.
    Chimirri A; De Sarro G; De Sarro A; Gitto R; Quartarone S; Zappalà M; Constanti A; Libri V
    J Med Chem; 1998 Aug; 41(18):3409-16. PubMed ID: 9719593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions among GYKI-52466, cyclothiazide, and aniracetam at recombinant AMPA and kainate receptors.
    Johansen TH; Chaudhary A; Verdoorn TA
    Mol Pharmacol; 1995 Nov; 48(5):946-55. PubMed ID: 7476926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones: novel AMPA receptor antagonists.
    Chimirri A; De Sarro G; De Sarro A; Gitto R; Grasso S; Quartarone S; Zappalà M; Giusti P; Libri V; Constanti A; Chapman AG
    J Med Chem; 1997 Apr; 40(8):1258-69. PubMed ID: 9111300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of GYKI 52466, a selective non-competitive antagonist of AMPA/kainate receptors, with conventional antiepileptic drugs in amygdala-kindled seizures in rats.
    Borowicz KK; Duda AM; Kleinrok Z; Czuczwar SJ
    Pol J Pharmacol; 2001; 53(2):101-8. PubMed ID: 11787948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and anticonvulsant activity of novel and potent 2,3-benzodiazepine AMPA/kainate receptor antagonists.
    Grasso S; De Sarro G; De Sarro A; Micale N; Zappalà M; Puia G; Baraldi M; De Micheli C
    J Med Chem; 1999 Oct; 42(21):4414-21. PubMed ID: 10543885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative patch clamp studies on the kinetics and selectivity of glutamate receptor antagonism by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) and 1-(4-amino-phenyl)-4-methyl-7,8-methyl-endioxyl-5H-2,3-benzodiaze pine (GYKI 52466).
    Parsons CG; Gruner R; Rozental J
    Neuropharmacology; 1994 May; 33(5):589-604. PubMed ID: 7523977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of 7,8-(methylenedioxy)-1-phenyl-3,5-dihydro-4H-2, 3-benzodiazepin-4-ones as novel and potent noncompetitive AMPA receptor antagonists.
    Wang Y; Konkoy CS; Ilyin VI; Vanover KE; Carter RB; Weber E; Keana JF; Woodward RM; Cai SX
    J Med Chem; 1998 Jul; 41(14):2621-5. PubMed ID: 9651166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses.
    Donevan SD; Rogawski MA
    Neuron; 1993 Jan; 10(1):51-9. PubMed ID: 7678966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist.
    Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
    Pol J Pharmacol; 1995; 47(6):501-7. PubMed ID: 8868372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative allosteric modulation of wild-type and mutant AMPA receptors by GYKI 53655.
    Partin KM; Mayer ML
    Mol Pharmacol; 1996 Jan; 49(1):142-8. PubMed ID: 8569699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo.
    Weiss B; Alt A; Ogden AM; Gates M; Dieckman DK; Clemens-Smith A; Ho KH; Jarvie K; Rizkalla G; Wright RA; Calligaro DO; Schoepp D; Mattiuz EL; Stratford RE; Johnson B; Salhoff C; Katofiasc M; Phebus LA; Schenck K; Cohen M; Filla SA; Ornstein PL; Johnson KW; Bleakman D
    J Pharmacol Exp Ther; 2006 Aug; 318(2):772-81. PubMed ID: 16690725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization.
    Parsons CG; Danysz W; Quack G; Hartmann S; Lorenz B; Wollenburg C; Baran L; Przegalinski E; Kostowski W; Krzascik P; Chizh B; Headley PM
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1264-75. PubMed ID: 9400002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel potent AMPA/kainate receptor antagonists: synthesis and anticonvulsant activity of a series of 2-[(4-alkylsemicarbazono)-(4-amino-phenyl)methyl]-4,5-methylenedioxyphenylacetic acid alkyl esters.
    Micale N; Zappalà M; Grasso S; Puja G; De Sarro G; Ferreri G; De Sarro A; Toma L; De Micheli C
    J Med Chem; 2002 Sep; 45(20):4433-42. PubMed ID: 12238923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allosteric interactions between cyclothiazide and AMPA/kainate receptor antagonists.
    Yamada KA; Turetsky DM
    Br J Pharmacol; 1996 Apr; 117(8):1663-72. PubMed ID: 8732274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity.
    Nielsen EO; Varming T; Mathiesen C; Jensen LH; Moller A; Gouliaev AH; Wätjen F; Drejer J
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1492-501. PubMed ID: 10336544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and kainate receptors.
    Cai SX; Huang JC; Espitia SA; Tran M; Ilyin VI; Hawkinson JE; Woodward RM; Weber E; Keana JF
    J Med Chem; 1997 Oct; 40(22):3679-86. PubMed ID: 9357535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.